Veterinary Vaccines Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Vaccine Type (Livestock Vaccine, Companion Animal Vaccine), By Technology (Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Other), By Region & Competition, 2021-2031F

Key Insights	Details
Forecast Period	2027-2031
Market Size (2025)	USD 8.71 Billion
CAGR (2026-2031)	7.36%
Fastest Growing Segment	Live Attenuated Vaccine
Largest Market	North America
Market Size (2031)	USD 13.34 Billion

Market Overview

The Global Veterinary Vaccines Market is projected to grow from USD 8.71 Billion in 2025 to USD 13.34 Billion by 2031 at a 7.36% CAGR. Veterinary vaccines are biological preparations administered to animals to stimulate an immune response, thereby preventing or mitigating infectious diseases. The market for these products is primarily driven by the growing global demand for animal protein, increasing companion animal ownership, and the escalating prevalence of infectious and zoonotic diseases necessitating enhanced prevention strategies. According to the World Organisation for Animal Health (WOAH), between 2025 and 2026, over 2,000 outbreaks of highly pathogenic avian influenza were reported across 64 countries, leading to the loss of more than 140 million poultry.

This highlights the ongoing need for robust animal health interventions. However, a significant impediment to market expansion is the uneven global access to these critical vaccines, coupled with under-resourced veterinary infrastructure in many regions.

Key Market Drivers

Zoonotic Disease Burden and Vaccination Imperative
The escalating incidence of zoonotic diseases, transmissible between animals and humans, coupled with a rising prevalence of companion animal ailments, significantly propels the global veterinary vaccines market. These diseases pose substantial public health risks and economic burdens, driving the imperative for preventive vaccination strategies. According to the World Organisation for Animal Health's (WOAH) "State of the World's Animal Health Report," May 2026, rabies alone kills an estimated 59,000 people every year, underscoring the critical need for animal vaccination programs to control the disease at its source.

Rising Demand for Animal Protein and Food Security
Concurrently, the growing global demand for animal-derived protein and heightened food security concerns are major market accelerators. As the world population expands, the need for efficient and healthy livestock production intensifies, making disease prevention through vaccination crucial for maintaining herd health, optimizing productivity, and ensuring food safety. The Food and Agriculture Organization of the United Nations (FAO) reported in its "Meat Market Review," April 2026, that world meat production rose by 2.5 percent in 2025 from 2024 levels, reaching 387 million tonnes. This sustained demand directly influences investments in livestock health management, including comprehensive vaccination programs. The broader animal health sector, reflecting vaccine market dynamics, demonstrated robust activity, with Merck & Co., Inc. reporting Animal Health sales of $1.79 billion in the first quarter of 2026.

Download Free Sample Report

Key Market Challenges

A significant challenging factor in the Global Veterinary Vaccines Market is the uneven worldwide access to these critical preparations, compounded by under-resourced veterinary infrastructure in many regions. This systemic issue directly impedes the market's expansion by limiting the reach and effective administration of vital animal health interventions. In areas with insufficient veterinary services, the implementation and sustainability of large-scale vaccination programs are severely curtailed, suppressing the potential for market penetration and growth. According to the World Organisation for Animal Health (WOAH), in 2026, 18% of countries assessed reported declining veterinary capacity, with an additional 22% indicating reduced paraprofessional capacity. This deficit in trained personnel and supporting facilities means that a substantial portion of the global animal population remains underserved, unable to access available vaccines. Consequently, the market faces significant unrealized demand, as logistical and infrastructural barriers prevent effective product delivery and uptake.

Key Market Trends

Advancements in recombinant and nucleic acid-based vaccine technologies are fundamentally reshaping the global veterinary vaccines market by offering enhanced precision and efficiency in disease prevention. These innovative platforms allow for the rapid development of vaccines tailored to specific pathogen strains, improving efficacy against evolving infectious agents and reducing development timelines compared to traditional methods. Such technological shifts enable the creation of safer and more potent immunological interventions for a wider range of animal diseases. According to Ceva Animal Health, February 2025, in "Ceva Animal Health inaugurates Biogenovac, a state-of-the-art Genomics Laboratory to Create Tomorrow's Vaccines and Prevent Future Health Crises," the company allocates 10% of its annual turnover to research and development. This investment underscores the industry's commitment to leveraging advanced genetic and molecular techniques for next-generation vaccine solutions.

The development of thermostable vaccine formulations and novel delivery systems represents another critical trend, addressing long-standing logistical and administration challenges, particularly in regions with limited infrastructure. These innovations mitigate the reliance on cold-chain storage and transport, thereby expanding vaccine accessibility to remote areas and reducing spoilage. Furthermore, novel delivery methods, such as oral or intranasal applications, simplify administration, potentially increasing vaccination coverage rates and animal welfare. Research highlights the effectiveness of these advancements; according to the MDPI study "Thermostable Vaccines in Veterinary Medicine: State of the Art and Opportunities to Be Seized," August 2025, the pooled vaccine efficacy of thermostable veterinary vaccines was estimated to be 69%. This demonstrates the significant impact these developments have on the practicality and widespread implementation of vaccination programs.

Segmental Insights

The Live Attenuated Vaccine segment demonstrates significant and rapid growth within the Global Veterinary Vaccines Market due to its distinct advantages. These vaccines effectively mimic natural infections, inducing strong and long-lasting immunity in animals, which reduces the need for frequent re-vaccination. Their cost-effectiveness in production and administration further contributes to widespread adoption, especially in large-scale livestock vaccination programs. The ability to stimulate robust cell-mediated immune responses against various pathogens enhances their utility and drives their expanding market presence.

Regional Insights

North America holds a leading position in the Global Veterinary Vaccines Market due to its highly developed veterinary healthcare infrastructure and substantial expenditure on animal health. The region benefits from a large population of pet owners who prioritize preventive care, driving consistent demand for veterinary vaccines. Additionally, the presence of major animal health pharmaceutical companies and supportive regulatory frameworks from bodies such as the U.S. Department of Agriculture (USDA) facilitate vaccine development, distribution, and widespread adoption. These combined elements contribute to North America's market dominance.

Recent Developments

• In May 2026, Merck Animal Health received a recommendation for market authorization in the European Union for Nobivac NXT HCPChFelV, a feline vaccine utilizing self-amplifying RNA technology. This product, designed to protect cats against feline leukemia virus (FeLV) and other key infectious diseases, marks a significant breakthrough as the first veterinary vaccine containing self-amplifying RNA to receive such support from the European Medicines Agency. This development further expands advanced vaccine options within the global veterinary vaccines market.
• In March 2026, BioVaxys Technology Corp. and Adiverna LLC announced a research agreement focused on developing mRNA-based vaccines for companion animals. This collaboration targets critical diseases such as rabies, leptospirosis, and feline infectious peritonitis (FIV) in dogs and cats. The initiative leverages Adiverna's advanced mRNA platform, which offers the potential for dose-sparing and robust immune responses, aiming to revolutionize routine vaccinations and enhance the safety and effectiveness of veterinary vaccines in the global companion animal health sector.
• In November 2025, Zoetis launched Vanguard Recombishield, an innovative injectable vaccine in the U.S. designed to protect dogs against Bordetella bronchiseptica, commonly known as kennel cough. This product represents a significant advancement in the global veterinary vaccines market, as it is the first and only canine vaccine utilizing pertactin protein for an optimized immune response. The recombinant technology employed ensures a comfortable immunization experience for pets, further expanding the available options for companion animal health.
• In February 2025, Elanco Animal Health Incorporated entered into an agreement with Medgene to commercialize a highly pathogenic avian influenza (HPAI) vaccine for use in dairy cattle in the United States. Medgene's vaccine platform technology had previously secured approval from the U.S. Department of Agriculture (USDA), facilitating the accelerated development of the H5N1 vaccine. This collaboration aims to provide crucial tools to dairy producers facing the challenges of this devastating disease, strengthening the global veterinary vaccines market by offering a new solution for livestock protection and disease control.

Key Market Players

• Zoetis Inc.
• Merck & Co., Inc.
• Boehringer Ingelheim International GmbH
• Elanco Animal Health Incorporated
• Ceva Santé Animale
• Virbac S.A.
• HIPRA, S.A.
• Phibro Animal Health Corporation
• Vetoquinol S.A.
• Hester Biosciences Limited

By Vaccine Type	By Technology	By Region
Livestock Vaccine Companion Animal Vaccine	Live Attenuated Vaccines Inactivated Vaccines Toxoid Vaccines Recombinant Vaccines Other	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Veterinary Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Veterinary Vaccines Market, By Vaccine Type:

• Livestock Vaccine
• Companion Animal Vaccine

• Veterinary Vaccines Market, By Technology:

• Live Attenuated Vaccines
• Inactivated Vaccines
• Toxoid Vaccines
• Recombinant Vaccines
• Other

• Veterinary Vaccines Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE